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Abstract
Background: Cervical cancer is the second most common gynecological cancer amongst women
world-wide. Despite optimized protocols, standard treatments still face several disadvantages.
Therefore, research aims at the development of immune-based strategies using tumor antigen-
loaded dendritic cells for the induction of cellular anti-tumor immunity.
Results: In this study, we used dendritic cells loaded with the HLA-A2-restricted HPV type 16
E711–20 peptide in order to induce an in vitro CD8+ T cell response. For this purpose, peptide-pulsed
dendritic cells were co-cultured with autologous CD8+ T cells. After 5 weekly stimulations with
peptide-pulsed mature dendritic cells, cultured T cells were analyzed for antigen specificity by an
IFN-γ ELISPOT assay. Using this ELISPOT assay, we were able to detect E7-specific IFN-γ-secreting
CD8+ T cells in 5/5 healthy donors.
Conclusion: We show that peptide-pulsed mature dendritic cells are able to stimulate a HPV type
16 E7 peptide-specific immune response in vitro. These experiments describe an efficient culture
protocol for antigen-specific T cells for use in pre-clinical vaccination research and confirm the
need for sensitive T cell assays for detection of tumor-specific immune responses in vitro.
Background
Cervical cancer contributes to approximately 12% of the
global cancer burden in women and represents the second
most frequent gynecological malignancy in the world
[1,2]. At an early stage, cervical cancer is treated by means
of surgery and radiotherapy [3]. In a more advanced stage,
one uses a combination therapy of cisplatinum-contain-
ing chemotherapy and radiotherapy [4]. Despite techno-
logical progress in conventional treatment modalities,
more than 35% of patients develop a metastasizing malig-
nancy with poor results after treatment. An additional dis-
advantage of radio- and chemotherapy is a pronounced
and long-lasting negative effect on the immune system.
For these reasons, current research aims at the develop-
ment of new and more efficient strategies. In this context,
dendritic cells (DC) loaded with tumor antigens for acti-
vation and/or expansion of tumor-specific T cells are cur-
Published: 26 October 2006
Molecular Cancer 2006, 5:49 doi:10.1186/1476-4598-5-49
Received: 01 November 2004
Accepted: 26 October 2006
This article is available from: http://www.molecular-cancer.com/content/5/1/49
© 2006 Cools et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 8
(page number not for citation purposes)
Molecular Cancer 2006, 5:49 http://www.molecular-cancer.com/content/5/1/49rently the subject of intensive research in the field of
cellular immunotherapy [5-7].
One of the major risk factors for the development of cer-
vical cancer is infection with human papillomavirus
(HPV). More than 20 oncogenic HPV genotypes have
been characterized, while HPV type 16 (HPV-16) and type
18 (HPV-18) are the most prevalent in cervical cancer [8].
In HPV-16 positive tumors, the E7 oncoprotein is consti-
tutively expressed in cervical tumor cells [9] and is respon-
sible for transformation of these cells [10]. Moreover,
HPV-16 E7-specific cytotoxic T lymphocytes (CTL) have
been demonstrated in the peripheral blood, the lymph
nodes and the tumor tissue of HPV-16-positive cervical
carcinoma patients [11,12]. An effective HPV-specific cel-
lular immune response can be generated after active
immunization [13-16]. For these reasons, the HPV-16 E7
protein is a target of choice for the development of a spe-
cific immune therapy directed against cervical cancer.
Stimulation of the immune system against specific tumor
antigens might become a suitable secondary (or even pri-
mary) therapy to treat cancer. Because tumor cells do not
efficiently function as antigen-presenting cells (APC) for
the activation of CTL, a vigorous immune response is gen-
erally absent or defective. To overcome this problem,
transfer of tumor antigens from tumor cells to profes-
sional APC, like DC, might be a valuable strategy [17].
DC are the most efficient antigen-capturing and -present-
ing cells of the immune system and are potent inducers of
(primary) immune responses directed against tumors and
viral antigens [18]. In their immature state, DC are skilled
in antigen uptake by means of endocytosis and phagocy-
tosis. After uptake, antigens are processed by DC to pep-
tide fragments which are bound to major
histocompatibility complex (MHC) class I and II mole-
cules. After transport to the plasma membrane, these pep-
tide-MHC complexes can be recognized by a T cell
receptor (TCR) with high specificity for the antigenic pep-
tide-MHC complex. If antigen uptake and presentation is
associated with danger signals, provided by microbial
components such as lipopolysaccharide (LPS) [19], DC
are activated and an effective immune response can be
induced.
In this study, we used in vitro cultured mature DC loaded
with an HLA-A*0201-restricted HPV-16 E7 peptide for the
in vitro activation of antigen-specific IFN-γ-producing
CD8+ T cells. After several rounds of in vitro stimulation of
CD8+ T cells using peptide-pulsed mature DC, the pres-
ence of HPV-16 E7 peptide-specific T cells was monitored
using an IFN-γ enzyme-linked immunospot (ELISPOT)
assay.
Results
Phenotypic analysis of mature monocyte-derived DC for T 
cell stimulation
Mature DC were differentiated starting from adherent
monocytes as described in the Methods section [20]. Cul-
tured DC were phenotypically characterized for the
expression of typical DC membrane markers (HLA-DR,
CD80, CD83 and CD86) by flow cytometry (Figure 1).
Analysis was restricted to DC by gating based on charac-
teristic forward and side scatter clustering (Figure 1: R1
gate in forward vs side scatter dot plot). The mature DC
population was negative for the monocyte marker CD14
and positive for costimulatory molecules HLA-DR, CD80
and CD86 and the adhesion receptor CD83. Moreover,
the final DC populations displayed minimal contamina-
tion of T and B cells as analyzed by CD3 and CD19 expres-
sion on the cultured DC population (Figure 1: no gate).
Peptide-pulsed DC efficiently present a MHC class I-
restricted E7 peptide to CD8+ T cells
First, we evaluated if our cultured mature DC population
was able to present the YMLDLQPETT peptide to CD8+ T
cells in a MHC class I-dependent way. For this, E7 peptide-
pulsed mature DC (2.104 cells) as well as non-pulsed
mature DC (2.104 cells) were co-cultured with an HLA-
A*0201+ HPV-16 E7 YMLDLQPETT peptide-specific T cell
clone (2.105 cells) for 6 hours in 96-round bottom wells.
As showed by the production of IFN-γ by the T cell clone,
E7-peptide-pulsed mature DC were able to stimulate these
antigen-specific T cells (Figure 2, p = 0.001).
Detection of immune responses against HPV-16 
immunodominant E7 peptide
Previously, we reported a DC-based T cell activation pro-
tocol for influenza matrix protein M1 peptide-specific T
cells [21]. We wanted to evaluate whether this T cell acti-
vation protocol was equally efficient in stimulating HPV-
16 E7-specific autologous CD8+ T cells. However, after a 7
day in vitro stimulation period of peripheral blood mono-
nuclear cells (PBMC) with HPV-16 E7 peptide-pulsed
mature DC, we were not able to detect an HPV-16 E7-spe-
cific immune response (data not shown). We therefore
added to the protocol 4 additional weekly stimulations
with HPV-16 E7-peptide-pulsed mature DC and imple-
mented an IFN-γ ELISPOT technique for detection of anti-
gen-specific IFN-γ-secreting T cells.
DC were differentiated starting from monocytes and
matured with a maturation cocktail consisting of IL-1, IL-
6, TNF-α and PGE2 [22]. Co-cultures were set up in multi-
ple 96-round-bottomed wells. In each well, 15.103 HPV-
16 E7-peptide-pulsed DC were cocultured together with
15.104 autologous CD8+ T cells, isolated using magnetic
bead selection from cryopreserved autologous PBMC (Fig-
ure 3). Growth factors (IL-2 and IL-7) were added weeklyPage 2 of 8
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Immunophenotypic analysis of dendritic cellsFigure 1
Immunophenotypic analysis of dendritic cells. Plastic adherent monocytes were cultured in the presence of GM-CSF 
and IL-4 for 6 days, followed by activation with a cytokine cocktail consisting of IL-1, IL-6, TNF-α and PGE2 for 24 hours (filled 
histogram). Analysis of typical DC membrane markers (CD80, 83, 86 and HLA-DR) and the monocyte marker CD14 was 
determined on R1 as shown in the forward vs side scatter dot plot, CD3 and CD19 on the ungated population. An isotype 
















Molecular Cancer 2006, 5:49 http://www.molecular-cancer.com/content/5/1/49to the T cell medium starting from week 2, together with
a total of 4 additional weekly stimulations with cryopre-
served HPV-16 E7 peptide-pulsed DC. We evaluated the
presence of a detectable immune response by determining
the presence of IFN-γ-producing cells after restimulation
with control or E7 peptide-pulsed targets by means of an
IFN-γ ELISPOT. For this analysis we used non-pulsed
K562-A*0201 cells as control targets and K562-A*0201
cells [23] pulsed with the HPV-16 E7 peptide as HPV-16
E7 peptide-specific target cells in a 10:1 effector:target cell
ratio. Furthermore, the effector T cell population was phe-
notypically evaluated in order to address the nature of the
effector T cell population with certainty. Figure 3 shows
that the majority of effector cells exists of CD8β+ T cells.
CD8β is a specific marker for cytotoxic T cells as it is not
expressed by CD8α+ NK cells or CD4+ T helper cells.
Using the IFN-γ ELISPOT assay in several individual exper-
iments (n = 48) tested per blood donor, a significant dif-
ference was detected between the number of spot-forming
CD8+ T cells (SFC: spot-forming cells) in response to HPV-
16 E7-peptide-pulsed target cells as compared to control
targets (Table 1). Figure 4 shows a representative picture
of a positive well per blood donor as compared to a con-
trol well on the ELISPOT plate. These results confirm that
HPV-16 E7-specific T cells can be sufficiently activated
and expanded by multiple stimulations with peptide-
pulsed mature DC to a detectable level for analysis with
an IFN-γ ELISPOT assay.
Discussion
Adequate immune monitoring techniques are of utmost
importance to validate phase I/II clinical trials designed to
test T cell-based vaccines for HPV-related malignancies.
Such endpoints include the measurement of HPV-specific
CTL- and T helper-mediated immune responses. Rou-
tinely used techniques such as ELISA and RT-PCR, do not
provide information regarding the frequencies of
cytokine-producing cells, in contrast to sensitive methods
such as ELISPOT.
In this study, we show efficient detection of HPV-16 E7
peptide-specific IFN-γ-producing autologous T cells after
multiple stimulations with HPV-16 E7-peptide-pulsed
mature DC using an IFN-γ ELISPOT assay (Figure 4 and
Table 1). In contrast, we could not detect HPV-16 E7-spe-
cific T cells with a previously used IFN-γ ELISA nor with a
LDH release cytotoxicity assay (data not shown). This
laborious detection of a HPV-16 E7-specific immune
response in healthy donors could be due to multiple fac-
tors. The weak sensitivity of bulk assays such as ELISA and
LDH release lysis assay can be an influencing factor. The
sensitivity of ELISPOT is indeed higher than that of an
ELISA. It is necessary to have at least 400 cells in an ELISA
system to produce 1 pg of cytokine. In contrast, in an ELIS-
POT assay, one assumes that 1 IFN-γ-secreting cell is
detectable among 5.105 cells [24]. Another important lim-
iting factor is the low precursor frequency of HPV-specific
CTL in healthy volunteers [8]. For example, one stimula-
tion with peptide-pulsed mature DC does probably not
induce sufficient expansion of HPV-16 E7-specific T cells.
Therefore, the T cell stimulation protocol included a total
of 5 weekly stimulations with HPV-16 E7-peptide-pulsed
mature DC. Moreover, our results are in agreement with
previous studies demonstrating the induction of an HPV-
16 E7-specific immune response in healthy volunteers
after multiple in vitro stimulations with autologous anti-
gen-loaded mature DC [14,15]. However, in contrast to
Schoell et al. [14], we have used human AB serum instead
of fetal calf serum in our experiments, in order to pave the
way to future clinical application of this culture protocol.
Moreover, the nature of the effector T cell population was
more critically evaluated. By using the CD8β marker, we
ascertained that the majority of the IFN-γ-producing effec-
tor population consists of CD8β+ T cells. Also, we
excluded aspecific IFN-γ production by CD4+ T helper
cells or NK cells by subtracting control values for our esti-
mation of effector CD8+ T cell frequencies.
Conclusion
Taken together, we showed that peptide-pulsed mature
DC are able to induce a cellular response against HPV-16
in 5/5 healthy volunteers, as detected by E7-specific IFN-γ
producing CD8+ T cells in an ELISPOT analysis. The
importance of this study is that it presents an efficient DC-
based culture protocol for tumor antigen-specific T cells in
pre-clinical vaccination studies. Moreover, our observa-
IFN-γ production by an HPV type 16 E7 peptide-specific HLA-A2+ T ell clone shows hat peptide-pulsed mature DC efficiently bind a d present the E7 peptide to T cellsFigure 2
IFN-γ production by an HPV type 16 E7 peptide-spe-
cific HLA-A2+ T cell clone shows that peptide-pulsed 
mature DC efficiently bind and present the E7 pep-
tide to T cells. HPV-16 E7-peptide-pulsed or non-pulsed 
mature DC were used as stimulator cells. Mature DC were 
co-incubated with a HPV-16 E7-specific CD8+ CTL clone. 
After 6 h, IFN-γ released in the co-culture was determined 
by IFN-γ ELISA. The T cell clone produced 2364 ± 28 pg/mL 
IFN-γ upon E7 peptide-pulsed mature DC stimulation com-
pared to 83 ± 21 pg/mL IFN-γ upon control stimulation (p-
value = 0.001).
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ods, such as ELISPOT, for the detection of tumor specific
immune responses in vitro.
Methods
Cell lines
K562-HLA-A*0201 cells were kindly provided by Dr. C.
Britten (Johannnes-Gutenberg University, Mainz, Ger-
many) [23]. Cells were cultured in complete medium con-
sisting of Iscove's modified Dulbecco's medium
supplemented with L-glutamine (IMDM; Invitrogen, Pais-
ley, UK), gentamicin (10 µg/mL, Invitrogen), amphoter-
icin B (1.25 µg/mL Fungizone; Invitrogen) and 10 % heat
inactivated fetal calf serum (FCS; Sera Lab, Sussex, UK)
and the neomycin analogue G418 (0.5 mg/mL, Invitro-
gen). Cells were maintained in logarithmic phase growth
at 37°C in a humidified atmosphere supplemented with
5% CO2.
HPV type 16 E7 peptide-specific T cell clone
The CD8+ D4 T cell clone recognizing the immunodomi-
nant HLA-A*0201-restricted HPV-16 E7 epitope (YMLD-
LQPETT) was a kind gift of Dr. S. Youde (University of
Wales College of Medicine, Cardiff, UK). Cloned T cells
(1.106) were expanded to large numbers in tissue culture
flasks containing 50 mL IMDM supplemented with 10%
human (h)AB serum (Sigma, Cambridge, UK) with
20.106 fresh irradiated (30 Gy) allogeneic peripheral
blood mononuclear cells (PBMC) from 2 donors, phyto-
hemagglutin A (PHA) (1 µg/mL, Sigma) and interleukin
(IL)-2 (200 U/mL, Biosource, Camarillo CA, USA). Fresh
medium and IL-2 were added on day 5. On day 7, the T
cells were transferred to a 24-well plate at 2.106 cells/well
and cultured in the presence of 100 U/mL IL-2 for up to
14 days.
Source of primary cells
Peripheral blood mononuclear cells (PBMC) were
obtained from hemochromatosis patients after informed
consent or from buffy coats provided by the Antwerp
Blood Transfusion Center (Red Cross). Mononuclear cells
were isolated by Ficoll-Hypaque gradient separation
(LSM, ICN Biomedicals, Costa Mesa, CA, USA). Mono-
cytes were directly isolated and used for DC culture, as
described below.
In vitro culture of DC
Immature monocyte-derived DC were cultured from
monocytes as described by Romani et al. [20] with minor
modifications. Briefly, PBMC were allowed to adhere in
serum-free AIM-V medium (Invitrogen) for 2 h at 37°C.
The non-adherent cell fraction was cryopreserved in a
solution consisting of 90% FCS and 10% DMSO and
stored at -80°C until later use in DC/T cell co-cultures,.
Adherent monocytes were further cultured for 6 days in
IMDM supplemented with 5% hAB serum (Sigma). One
hundred ng/mL granulocyte-macrophage colony-stimu-
lating factor (GM-CSF; Leucomax, Novartis Pharma,
Basel, Switzerland) and 1000 U/mL IL-4 (R&D Systems,
Minneapolis, MN, USA) were added to the cultures. Mat-
uration of immature DC was induced on day 6 by adding
a maturation cocktail consisting of 100 U/mL IL-1 (Bio-
source Europe, Nivelles, Belgium), 500 U/mL IL-6 (Bio-
source), 2.5 ng/mL tumor necrosis factor (TNF)-α (Roche
Molecular Biochemicals, Mannheim, Germany) and 10-7
M prostaglandin E2 (PGE2) (Sigma, St. Louis, MO, USA),
as previously described by Jonuleit et al [22]. Mature DC
were either directly used in DC/T cell co-culture or cryop-
reserved for further restimulations as previously described
[21]. Briefly, cells were resuspended in a solution consist-
ing of 90% FCS and 10% DMSO and were stored at -80°C
until use.
Flow cytometry
Screening of blood donors for HLA-A*0201-positivity was
performed on whole blood by incubation with the super-
natant of the BB7-2 hybridoma (anti-HLA-A*0201;
ATCC, Manassas, VA, USA), followed by staining with flu-
orescein (FITC)-conjugated rabbit anti-mouse immu-
noglobulins (DAKO Cytomation, Heverlee, Belgium). For
phenotyping of cultured DC and T cell populations, the
following murine anti-human monoclonal antibodies
were used for direct immunofluorescence staining: CD80-
FITC, CD83-phycoerythrin (PE) (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA), CD86-PE, CD3-peridinin
chlorophyll-a protein (PerCP), CD14-PE, CD19-FITC,
HLA-DR-PE, CD4-FITC, CD16-FITC, CD56-FITC, CD8-PE
and CD8β-PE. Non-reactive isotype-matched antibodies
were used as controls. All antibodies were purchased from
Becton Dickinson (Erembodegem, Belgium), unless
stated otherwise. Cells were stained with antibody for 15
min at 4°C, washed and surface labelling of living cells
was analyzed by flow cytometry on a FACScan (Becton
Dickinson).
Peptide pulsing of DC and K562-HLA-A*0201 cells
An HPV-16 HLA-A*0201-restricted E7 protein-specific
peptide (E7; amino acids (aa) 11–20, YMLDLQPETT) was
used for activation or for detection of HPV-16 E7 peptide-
specific T cells, when pulsed on DC or on K562-HLA-
A*0201 cells respectively. The peptides (>95% pure) were
purchased from Eurogentec (Seraing, Belgium) and were
dissolved in 100% DMSO to 10 mg/mL, further diluted to
1 mg/mL in serum-free IMDM and stored in aliquots at -
80°C. The peptides were used at a final concentration of
20 µg/mL. DC or K562-HLA-A*0201 cells were washed
once with IMDM and subsequently incubated (1.106
cells/mL) for 2 h at room temperature in 5-mL polysty-
rene tubes with 20 µg/mL peptide in serum-free IMDM
supplemented with 2.5 µg/mL β2-microglobulin (Sigma).Page 5 of 8
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used, respectively, as stimulators for T cells in DC/T cell
co-cultures and as antigen-specific stimulator cells in an
IFN-γ ELISPOT assay.
CD8+ T cell isolation
For DC/T cell co-culture experiments, frozen non-adher-
ent PBMC were thawed and CD8+ T cells were isolated by
magnetic separation using CD8 microbeads (Miltenyi
Biotec, Bergisch Gladbach, Germany) according to manu-
facturer's instructions. Routinely, 10–20.106 CD8+ T cells
were obtained starting from 100.106 cryopreserved non-
adherent cells with purity levels ≥ 85%.
Induction of MHC class I-restricted HPV-16 E7-peptide-
specific T cells
HPV-16 E7 peptide-pulsed mature monocyte-derived DC
were used for stimulation of autologous CD8+ T cells.
Multiple co-cultures of 15.103 peptide-pulsed DC with
15.104 purified CD8+ T cells were initiated in AIM-V
medium supplemented with 5% hAB serum in 96-round
bottom wells (Costar, Corning, NY, USA). After 7 days of
Table 1: Analysis of HPV-16 E7 antigen-specific IFN-γ secretion by means of the IFN-γ ELISPOT assay
DONOR Fifth stimulation Positive cultures/total 
cultures
Percentage of antigen-specific spot 
forming cells (SFC) in positive wells
1 2/48 0.03–0.08 [0.06]
2 3/48 0.05–0.06 [0.05]
3 6/48 0.02–0.04 [0.03]
4 7/48 0.03–0.18 [0.08]
5 2/2 0.12–0.14 [0.13]
Responses were considered positive if a minimum of 15 SFC were counted after the control had been subtracted and if the ratio of SFC in positive 
wells to that in control wells was > 3. The range of the percentage of antigen-specific SCF is also given, with the mean percentage between square 
brackets, calculated as the ratio between the number of spots in a positive well and the total number of T cells in that well.
Representative example of the phenotypic analysis of the effector T cell populationFigure 3
Representative example of the phenotypic analysis of the effector T cell population. CD8+ T cells were isolated by 
magnetic separation using CD8 microbeads. Dot plots were gated on the lymphocyte population based on forward and side 
scatter properties. The indicated percentages are within the lymphocyte population.
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served peptide-pulsed mature DC. At this point, addi-
tional cytokines were added to the co-cultures: 5 ng/mL
IL-7 (Biosource) and 10 U/mL IL-2 (Biosource). Restimu-
lation of cultured T cells was done weekly. After 5 stimu-
lations, T cells were analyzed for antigen specificity in an
IFN-γ ELISPOT assay.
IFN-γ release assays
HPV-16 E7 peptide-pulsed mature DC were used as stim-
ulator cells for the E7 peptide-specific D4 CTL, while non-
pulsed mature DC were used as control cells. CTL (2.105
cells) were co-incubated with stimulator cells (2.104 cells)
in 96-round bottom plates for 6 hours at 37°C in a total
volume of 200 µL IMDM supplemented with 5% hAB
serum. Triplicate supernatant samples from these co-cul-
tures were tested for IFN-γ secretion by an IFN-γ enzyme-
linked immunosorbant assay (ELISA) (Biosource). Meas-
urements are presented as pg/mL released IFN-γ by 2.105
CTL per 6 hours. Results are expressed as the mean ±
standard deviation. Comparisons were validated using
Student's t test.
IFN-γ ELISPOT assay
K562-HLA-A*0201 cells, pulsed with HPV-16 E7 protein-
specific peptide, were used as stimulators of cultured
CD8+ T cells in an IFN-γ ELISPOT assay, while non-pulsed
K562-HLA-A*0201 cells were used as control cells. Stimu-
lator and responder cells were washed and resuspended in
AIM-V supplemented with 5% hAB serum. Then,
responder T cells (5.104 cells) were co-incubated with
stimulator cells (1.104 cells) overnight at 37°C in anti-
IFN-γ antibody coated 96-well PVDF-plates (Millipore,
Bedford, MA, USA) in a total volume of 100 µL. These
plates were further analyzed for IFN-γ secretion by IFN-γ
ELISPOT staining technique (Diaclone, Amsterdam, The
Netherlands) according to manufacturer's instructions.
Frequencies of antigen-specific IFN-γ-secreting cells were
calculated based on the number of responder cells and the
number of spots per well after subtraction of background.
Responses were considered positive if a minimum of 15
spot-forming cells (SFC) were counted after the control
had been subtracted and if the ratio of SFC between posi-
tive experiments and their respective control was larger
than 3.
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